New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis

Stefano Perlini, Roberta Mussinelli, Francesco Salinaro

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, cardiac amyloidosis is associated with left ventricular concentric “hypertrophy” (i.e. increased wall thickness), preserved (or mildly depressed) ejection fraction, reduced midwall fractional shortening and global longitudinal function, as well as evident diastolic dysfunction, up to an overly restrictive pattern of the left ventricular filling. Cardiac biomarkers such as troponins and natriuretic peptides are very robust and widely accepted diagnostic as well as prognostic tools. Owing to its dismal prognosis, accurate and early diagnosis is mandatory and potentially life-saving. Although pathogenesis is still not completely understood, direct cardiomyocyte toxicity of the amyloidogenic precursor proteins and/or oligomer aggregates adds on tissue architecture disruption caused by amyloid deposition. The clarification of mechanisms of cardiac damage is offering new potential therapeutic targets, and several treatment options with a relevant impact on prognosis are now available.

Original languageEnglish
Pages (from-to)267-272
Number of pages6
JournalCurrent Heart Failure Reports
Volume13
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Amyloidosis
Restrictive Cardiomyopathy
Diastolic Heart Failure
Amyloidogenic Proteins
Natriuretic Peptides
Prealbumin
Troponin
Left Ventricular Hypertrophy
Rare Diseases
Amyloid
Cardiac Myocytes
Signs and Symptoms
Early Diagnosis
Heart Failure
Biomarkers
Light
Proteins
Therapeutics

Keywords

  • Cardiac amyloidosis
  • Cardiac imaging
  • Cardiac toxicity
  • Diastolic function
  • Heart failure
  • NT-proBNP
  • Systolic function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine
  • Medicine(all)

Cite this

New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. / Perlini, Stefano; Mussinelli, Roberta; Salinaro, Francesco.

In: Current Heart Failure Reports, Vol. 13, No. 6, 01.12.2016, p. 267-272.

Research output: Contribution to journalReview article

Perlini, Stefano ; Mussinelli, Roberta ; Salinaro, Francesco. / New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. In: Current Heart Failure Reports. 2016 ; Vol. 13, No. 6. pp. 267-272.
@article{efa6e5554c364c808233f5a9bb83b628,
title = "New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis",
abstract = "Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, cardiac amyloidosis is associated with left ventricular concentric “hypertrophy” (i.e. increased wall thickness), preserved (or mildly depressed) ejection fraction, reduced midwall fractional shortening and global longitudinal function, as well as evident diastolic dysfunction, up to an overly restrictive pattern of the left ventricular filling. Cardiac biomarkers such as troponins and natriuretic peptides are very robust and widely accepted diagnostic as well as prognostic tools. Owing to its dismal prognosis, accurate and early diagnosis is mandatory and potentially life-saving. Although pathogenesis is still not completely understood, direct cardiomyocyte toxicity of the amyloidogenic precursor proteins and/or oligomer aggregates adds on tissue architecture disruption caused by amyloid deposition. The clarification of mechanisms of cardiac damage is offering new potential therapeutic targets, and several treatment options with a relevant impact on prognosis are now available.",
keywords = "Cardiac amyloidosis, Cardiac imaging, Cardiac toxicity, Diastolic function, Heart failure, NT-proBNP, Systolic function",
author = "Stefano Perlini and Roberta Mussinelli and Francesco Salinaro",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s11897-016-0311-y",
language = "English",
volume = "13",
pages = "267--272",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis

AU - Perlini, Stefano

AU - Mussinelli, Roberta

AU - Salinaro, Francesco

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, cardiac amyloidosis is associated with left ventricular concentric “hypertrophy” (i.e. increased wall thickness), preserved (or mildly depressed) ejection fraction, reduced midwall fractional shortening and global longitudinal function, as well as evident diastolic dysfunction, up to an overly restrictive pattern of the left ventricular filling. Cardiac biomarkers such as troponins and natriuretic peptides are very robust and widely accepted diagnostic as well as prognostic tools. Owing to its dismal prognosis, accurate and early diagnosis is mandatory and potentially life-saving. Although pathogenesis is still not completely understood, direct cardiomyocyte toxicity of the amyloidogenic precursor proteins and/or oligomer aggregates adds on tissue architecture disruption caused by amyloid deposition. The clarification of mechanisms of cardiac damage is offering new potential therapeutic targets, and several treatment options with a relevant impact on prognosis are now available.

AB - Systemic amyloidoses are rare and proteiform diseases, caused by extracellular accumulation of insoluble misfolded fibrillar proteins. Prognosis is dictated by cardiac involvement, which is especially frequent in light chain (AL) and in transthyretin variants (ATTR, both mutated, (ATTRm), and wild-type, (ATTRwt)). Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, cardiac amyloidosis is associated with left ventricular concentric “hypertrophy” (i.e. increased wall thickness), preserved (or mildly depressed) ejection fraction, reduced midwall fractional shortening and global longitudinal function, as well as evident diastolic dysfunction, up to an overly restrictive pattern of the left ventricular filling. Cardiac biomarkers such as troponins and natriuretic peptides are very robust and widely accepted diagnostic as well as prognostic tools. Owing to its dismal prognosis, accurate and early diagnosis is mandatory and potentially life-saving. Although pathogenesis is still not completely understood, direct cardiomyocyte toxicity of the amyloidogenic precursor proteins and/or oligomer aggregates adds on tissue architecture disruption caused by amyloid deposition. The clarification of mechanisms of cardiac damage is offering new potential therapeutic targets, and several treatment options with a relevant impact on prognosis are now available.

KW - Cardiac amyloidosis

KW - Cardiac imaging

KW - Cardiac toxicity

KW - Diastolic function

KW - Heart failure

KW - NT-proBNP

KW - Systolic function

UR - http://www.scopus.com/inward/record.url?scp=85000538679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000538679&partnerID=8YFLogxK

U2 - 10.1007/s11897-016-0311-y

DO - 10.1007/s11897-016-0311-y

M3 - Review article

C2 - 27900617

AN - SCOPUS:85000538679

VL - 13

SP - 267

EP - 272

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 6

ER -